Watson buys women's health-focused Uteron for up to $305m as it adopts Actavis name
This article was originally published in Scrip
Executive Summary
On the eve of Watson Pharmaceuticals' transition to a new name in honor of the company's $5.6 billion acquisition of global generics competitor Actavis in 2012, the US firm has announced a purchase worth up to $305 million that's meant to fill its brand-name drug pipeline and increase the company's presence in the women's health market.
You may also be interested in...
Nonprofit Medicines360 Provides Affordable Contraception, Women’s Health
Emerging Company Profile: Medicines360 and partner Allergan launched the IUD Liletta in 2015, so now the nonprofit pharmaceutical company is looking for additional contraceptives and women’s health products.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.